Загрузка...
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant
No countermeasures currently exist for the prevention or treatment of the severe sequelae of Filovirus (such as Ebola virus; EBOV) infection. To overcome this limitation in our biodefense preparedness, we have designed monoclonal antibodies (mAbs) which could be used in humans as immunoprotectants f...
Сохранить в:
| Главные авторы: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
National Academy of Sciences
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3251097/ https://ncbi.nlm.nih.gov/pubmed/22143789 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1108360108 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|